Transplantation for hepatocellular carcinoma: Management of patients on the waiting list

Liver Transplantation

Volumn 16, Issue SUPPL. 2, 2010, Pages

  Majno, Pietro ^a   Mentha, Gilles ^a   Toso, Christian ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ARTICLE; CHEMOEMBOLIZATION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; PATIENT CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

EID: 78651397140     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22163     Document Type: Article

References (44)

1. Llovet JM, Fuster J, Bruix J., Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 39: 1434-1440.
2. Toso C, Mentha G, Kneteman NM, Majno P., The place of downstaging for hepatocellular carcinoma. J Hepatol 2010; 52: 930-936.
3. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J., Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 631-636. (Pubitemid 32677888)
4. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G., Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10: 449-455. (Pubitemid 38380323)
5. Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M, et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 2004; 4: 782-787. (Pubitemid 38637578)
6. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-692. (Pubitemid 36874454)
7. Yamashiki N, Gaynor JJ, Kato T, Reddy KR, Sobhonslidsuk A, Levi D, et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004; 4: 774-781. (Pubitemid 38637577)
8. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, et al. M. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18: 502-512. (Pubitemid 39264345)
9. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909. (Pubitemid 39425785)
10. Lu DSK, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137. (Pubitemid 40593921)
11. Martin AP, Goldstein RM, Dempster J, Netto GJ, Katabi N, Derrick HC, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation-a clinical and histological examination. Clin Transplant 2006; 20: 695-705. (Pubitemid 44712269)
12. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267. (Pubitemid 44194595)
13. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279. (Pubitemid 46351654)
14. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pretransplant loco-regional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665-673.
15. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Impact of pre-transplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775. (Pubitemid 40975578)
16. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15: 859-868.
17. Freeman RB, Edwards EB, Harper AM., Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416-1421. (Pubitemid 44030324)
18. Washburn K, Edwards E, Harper A, Freeman RB., Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1652-1657.
19. Huo T-I, Huang Y-H, Su C-W, Lin H-C, Chiang J-H, Chiou Y-Y, et al. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 2008; 22: 469-475.
20. Llovet JM, Sala M, Fuster J, Navasa M, Pons F, Solé M, et al. Predictors of drop-out and survival of patients with hepatocellular carcinoma candidates for liver transplantation [abstract]. Hepatology 2003; 38: 763A.
21. Cheow PC, Al-Alwan A, Kachura J, et al. Ablation of hepatoma as a bridge to liver transplantation reduces drop-out from prolonged waiting time [abstract]. Hepatology 2005; 42: 333A.
22. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-128. (Pubitemid 34028315)
23. Aloia TA, Adam R, Samuel D, Azoulay D, Castaing D., A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 2007; 11: 1328-1332.
24. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
25. De Simone P, Vignali C, Petruccelli S, Carrai P, Coletti L, Montin U, et al. Cost analysis of tumor downsizing for hepatocellular carcinoma liver transplant candidates. Transplant Proc 2006; 38: 3561-3563. (Pubitemid 44908454)
26. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA., Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-2650. (Pubitemid 44571684)
27. Kulik L, Abecassis M., Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: S277-S282. (Pubitemid 39423397)
28. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS JR, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608. (Pubitemid 46776250)
29. Todo S, Furukawa H, for the Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240: 451-459.
30. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Nakanishi K, Yamashita K, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Surg; doi:10.1007/s00534-009-0168-5.
31. Chao SD, Roberts JP, Farr M, Yao FY., Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant 2007; 7: 1594-1600. (Pubitemid 46776249)
32. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739. (Pubitemid 34607087)
33. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171. (Pubitemid 34454013)
34. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261.
35. Lencioni R., Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
36. Oldhafer KJ, Chavan A, Frühauf NR, Flemming P, Schlitt HJ, Kubicka S, etal. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953-959. (Pubitemid 28559065)
37. Perez Saborido B, Meneu JC, Moreno E, Garcia I, Moreno A, Fundora Y., Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005; 190: 383-387. (Pubitemid 41139290)
38. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004; 78: 1780-1786. (Pubitemid 40041645)
39. Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005; 11: 1117-1126. (Pubitemid 41341763)
40. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49: 1185-1193.
41. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Tran Van Nhieu J, et al. Liver resection for transplantable hepatocellular carcinoma. Long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-746.
42. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51: 165-173.
43. Navasa M, Bruix J., Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. Hepatology 2010; 51: 12-15.
44. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-563. (Pubitemid 36701690)